404 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Mechanics Bank Trust Department

Mechanics Bank Trust Department acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 404 shares of the biopharmaceutical company’s stock, valued at approximately $288,000.

Other hedge funds have also added to or reduced their stakes in the company. AE Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 19.4% in the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 89 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 9.5% in the second quarter. Pacer Advisors Inc. now owns 16,464 shares of the biopharmaceutical company’s stock worth $17,304,000 after purchasing an additional 1,434 shares in the last quarter. Sei Investments Co. increased its stake in shares of Regeneron Pharmaceuticals by 2.2% in the second quarter. Sei Investments Co. now owns 24,944 shares of the biopharmaceutical company’s stock worth $26,214,000 after purchasing an additional 537 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 28.7% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 5,657 shares of the biopharmaceutical company’s stock valued at $5,946,000 after buying an additional 1,263 shares in the last quarter. Finally, Frank Rimerman Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 19,133.3% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 577 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 574 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $681.58 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $74.90 billion, a P/E ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. The firm’s fifty day moving average is $738.60 and its 200 day moving average is $948.80. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Analysts Set New Price Targets

Several research firms have issued reports on REGN. Citigroup dropped their target price on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.